ProMIS Neurosciences Inc. Common Shares (ON) (PMN)

Price$9.13

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)27.13%

Price vs S&P 500 (4W)-7.11%

VGM Score29.36

Market Capitalization$19.65M

All Metrics

Book Value / Share (Quarterly)$6.77

P/TBV (Annual)5.79x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.97

Price vs S&P 500 (YTD)25.52%

Net Profit Margin (TTM)-12900.00%

EPS (TTM)$-18.59

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-18.59

EPS (Annual)$-1.07

ROI (Annual)-352.02%

Net Profit Margin (5Y Avg)-12306.41%

Cash / Share (Quarterly)$7.12

ROA (Last FY)-97.01%

EBITD / Share (TTM)$-13.28

ROE (5Y Avg)-725.53%

Operating Margin (TTM)-12900.00%

Cash Flow / Share (Annual)$-13.06

P/B Ratio0.32x

P/B Ratio (Quarterly)1.88x

Net Income / Employee (Annual)$-2,202,100

Net Interest Coverage (TTM)-5.53x

ROA (TTM)-151.04%

EPS Incl Extra (Annual)$-1.07

Current Ratio (Annual)0.88x

Quick Ratio (Quarterly)9.69x

3-Month Avg Trading Volume0.13M

52-Week Price Return-23.92%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.20

P/S Ratio (Annual)1965.14x

Asset Turnover (Annual)0.01x

52-Week High$39.75

Operating Margin (5Y Avg)-12266.41%

EPS Excl Extra (Annual)$-1.07

26-Week Price Return35.06%

Quick Ratio (Annual)0.60x

13-Week Price Return-63.17%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.92x

Enterprise Value$-44.16M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-46400.00%

Cash / Share (Annual)$2.86

3-Month Return Std Dev82.66%

Net Income / Employee (TTM)$-6,769,300

ROE (Last FY)-352.02%

EPS Basic Excl Extra (Annual)$-1.07

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-18.59

Receivables Turnover (Annual)0.29x

ROI (TTM)-56.72%

P/S Ratio (TTM)1965.14x

Pretax Margin (5Y Avg)-12306.41%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$4.97

Price vs S&P 500 (52W)-48.28%

Year-to-Date Return33.67%

5-Day Price Return-12.30%

EPS Normalized (Annual)$-1.07

ROA (5Y Avg)-229.81%

Net Profit Margin (Annual)-46400.00%

Month-to-Date Return-15.54%

Cash Flow / Share (TTM)$-1.78

EBITD / Share (Annual)$-1.16

Operating Margin (Annual)-46300.00%

LT Debt / Equity (Annual)0.69x

ROI (5Y Avg)-711.40%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-18.59

P/TBV (Quarterly)5.79x

P/B Ratio (Annual)1.88x

Pretax Margin (TTM)-12900.00%

Book Value / Share (Annual)$12.61

Price vs S&P 500 (13W)-71.43%

Beta-0.13x

Revenue / Share (TTM)$0.00

ROE (TTM)-56.72%

52-Week Low$6.27

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-1.26est. -1.49

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PMNProMIS Neurosciences Inc. Common Shares (ON)	—	—	D	$9.13
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics for neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. The company uses its proprietary ProMIS platform to identify and target toxic misfolded proteins that drive neurodegeneration.